

## Press Release

# Strengthening the Supply of Medical Cannabis in Germany Vayamed Becomes Exclusive Wholesale Partner for Bedrocan Products in Germany

Berlin, April 23, 2026 – Vayamed GmbH, a subsidiary of Berlin-based medical cannabis company Sanity Group, will in future include cannabinoid-based medicinal products from manufacturer Bedrocan in its product portfolio for German pharmacies. Since 2026, Medios AG, a leading provider of specialty pharmaceuticals in Europe, has been the exclusive distribution partner of Bedrocan and is responsible for supplying Bedrocan products, including in Germany. As a distribution partner, Cannaflos – Gesellschaft für medizinisches Cannabis mbH supports Medios AG in building a nationwide distribution network; as part of this partnership, Vayamed will be integrated into the distribution network as exclusive wholesale partner.

The partners involved share the common goal of responsibly advancing the medical cannabis market in Germany and improving access to high-quality therapeutic options. “Our extensive network within the German pharmacy landscape, and in particular our close relationships with the medical community, can be ideally combined with the strong position of Medios and Cannaflos in distribution, research, and pharma services. Bedrocan will become a permanent component of the Vayamed product portfolio going forward,” explains Finn Hänsel, founder and CEO of Sanity Group.

### German Market Launch of Bedrocan® Forte 25:1

A particular focus is on establishing Bedrocan® Forte 25:1 cannabis flowers, which will soon be offered on the German market. Bedrocan® Forte is the further development of the established medicinal product Bedrocan® 22:1, which will also be added to Vayamed's portfolio, and provides an alternative for patients who require higher dosages.

### About Vayamed

Vayamed specializes in the development and distribution of innovative cannabinoid-based medicinal products for the European market and is committed to making medical cannabis widely accessible to physicians, pharmacies, and patients as a reliable provider. To achieve this, Vayamed collaborates with an established network of international partners. The company's focus is on improving patients' quality of life through cannabinoid-based therapies. Further information is available at [www.vayamed.com](http://www.vayamed.com).